Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving Average – Should You Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $22.32 and traded as high as $23.75. Capricor Therapeutics shares last traded at $23.52, with a volume of 603,063 shares trading hands.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research analyst reports. Roth Mkm increased their price objective on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Industrial Alliance Securities set a $48.00 price target on Capricor Therapeutics in a research note on Wednesday, December 3rd. HC Wainwright lifted their price objective on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, December 3rd. Maxim Group boosted their price objective on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Finally, Oppenheimer increased their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $40.82.

Capricor Therapeutics Stock Performance

The business has a 50-day simple moving average of $22.32 and a 200-day simple moving average of $12.26. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -13.07 and a beta of 0.22.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). Research analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CAPR. Geode Capital Management LLC lifted its holdings in shares of Capricor Therapeutics by 6.8% in the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after purchasing an additional 61,701 shares during the last quarter. Pier Capital LLC lifted its position in Capricor Therapeutics by 35.0% during the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after acquiring an additional 128,837 shares during the period. Goldman Sachs Group Inc. increased its stake in Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after buying an additional 116,373 shares during the period. Two Sigma Investments LP raised its stake in shares of Capricor Therapeutics by 128.3% during the 3rd quarter. Two Sigma Investments LP now owns 355,796 shares of the biotechnology company’s stock worth $2,565,000 after buying an additional 199,959 shares in the last quarter. Finally, Jump Financial LLC lifted its stake in shares of Capricor Therapeutics by 42.6% in the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock valued at $2,309,000 after purchasing an additional 69,515 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.